JHVEPhoto/iStock Editorial via Getty Images
The FDA has reportedly approved an injectable formulation of Bristol-Myers Squibb’s (NYSE:BMY) oncology drug Opdivo.
Previously, the PD-1 inhibitor drug was only available through IV infusion.
The injectable formulation, which will be branded Opdivo Qvantig, has been approved for all previously approved
